The following are notable events in the Timeline of immunology:
1550 BCE – The
Ebers papyrus recommends placing a poultice on a tumor and then making an incision, which would induce infection and cause regression of the tumor.[1]
1829 – Another case of
spontaneous remission of breast cancer after a patient refused surgery and the tumor ruptured, became infected and during a febrile illness with purulent discharge, it shrunk and disappeared after a few weeks. (
Guillaume Dupuytren)[4][5][6]
1837 – Description of the role of microbes in putrefaction and fermentation (
Theodore Schwann)
1838 – Confirmation of the role of yeast in fermentation of sugar to alcohol (
Charles Cagniard-Latour)
1850 – Demonstration of the contagious nature of puerperal fever (childbed fever) (
Ignaz Semmelweis)
1857–1870 – Confirmation of the role of microbes in fermentation (
Louis Pasteur)
1867 – Aseptic practice in surgery using carbolic acid (
Joseph Lister)
1868 – Busch discovered that a sarcoma patient being surgically intervened to remove the tumor, after being exposed to a patient suffering from
erysipelas, got a skin infection and her tumor disappeared. He inoculated some other cancer patients with many successes.[7][4]
1876 – Demonstration that microbes can cause disease-anthrax (
Robert Koch)
1878 – Confirmation and popularization of the germ theory of disease (
Louis Pasteur)
1880 – 81 Theory that bacterial virulence could be attenuated by culture in vitro and used as vaccines. Used to make chicken cholera and anthrax "vaccines" (
Louis Pasteur)
1882 – Identification of Streptococcus pyogenes as the causative agent of
erysipelas (
Friedrich Fehleisen). He repeats Busch experiments inoculating cancer patients with eryisipelas, noting tumor regression in many of them.[8]
1883–1905 – Cellular theory of immunity via phagocytosis by macrophages and microphages (polymorhonuclear leukocytes) (
Elie Metchnikoff)
1885 – Introduction of concept of a "therapeutic vaccination". Report of a live "attenuated" vaccine for rabies (
Louis Pasteur and
Pierre Paul Émile Roux).
1960 – Discovery of lymphocyte "blastogenic transformation" and proliferation in response to mitogenic lectins-phytohemagglutinin (PHA) (
Peter Nowell)
2010 – The first autologous cell-based cancer vaccine,
Provenge, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer.
2010 – First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of stage IV melanoma
2011 –
Carl H. June reports first successful use of CAR T-cells expressing the 4-1BB costimulatory signaling domain for the treatment of CD19+ malignancies
2014 – A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma.
Pembrolizumab and
nivolumab are approved within months of each other.
2016 – The role of dendritic cell expressed CTLA-4 in Th immune polarization is first described
2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (
atezolizumab), is approved for the treatment of bladder cancer
2017 – First autologous CAR T-cell therapy
tisagenlecleucel approved for the treatment of pediatric B-ALL; second autologous CAR T-cell therapy
axicabtagene ciloleucel (Yescarta) is approved.
2020 – The first
mRNA vaccines (
BNT162b2,
mRNA-1273), are developed for
SARS-CoV-2 infection; this new technology completed design, testing, and emergency approval in under one year.
^Hoption Cann SA, van Netten JP, van Netten C (1 January 2006). "Acute infections as a means of cancer prevention: opposing effects to chronic infections?". Cancer Detection and Prevention. 30 (1): 83–93.
doi:
10.1016/j.cdp.2005.11.001.
PMID16490323.
^Dupuytren G. "De la gangrène spontanée générale et partielle des tumeurs cancéreuses du sein". J Hebdom Med. 4.
^Wei MQ, Mengesha A, Good D, Anné J (January 2008). "Bacterial targeted tumour therapy-dawn of a new era". Cancer Letters. 259 (1): 16–27.
doi:
10.1016/j.canlet.2007.10.034.
PMID18063294.
The following are notable events in the Timeline of immunology:
1550 BCE – The
Ebers papyrus recommends placing a poultice on a tumor and then making an incision, which would induce infection and cause regression of the tumor.[1]
1829 – Another case of
spontaneous remission of breast cancer after a patient refused surgery and the tumor ruptured, became infected and during a febrile illness with purulent discharge, it shrunk and disappeared after a few weeks. (
Guillaume Dupuytren)[4][5][6]
1837 – Description of the role of microbes in putrefaction and fermentation (
Theodore Schwann)
1838 – Confirmation of the role of yeast in fermentation of sugar to alcohol (
Charles Cagniard-Latour)
1850 – Demonstration of the contagious nature of puerperal fever (childbed fever) (
Ignaz Semmelweis)
1857–1870 – Confirmation of the role of microbes in fermentation (
Louis Pasteur)
1867 – Aseptic practice in surgery using carbolic acid (
Joseph Lister)
1868 – Busch discovered that a sarcoma patient being surgically intervened to remove the tumor, after being exposed to a patient suffering from
erysipelas, got a skin infection and her tumor disappeared. He inoculated some other cancer patients with many successes.[7][4]
1876 – Demonstration that microbes can cause disease-anthrax (
Robert Koch)
1878 – Confirmation and popularization of the germ theory of disease (
Louis Pasteur)
1880 – 81 Theory that bacterial virulence could be attenuated by culture in vitro and used as vaccines. Used to make chicken cholera and anthrax "vaccines" (
Louis Pasteur)
1882 – Identification of Streptococcus pyogenes as the causative agent of
erysipelas (
Friedrich Fehleisen). He repeats Busch experiments inoculating cancer patients with eryisipelas, noting tumor regression in many of them.[8]
1883–1905 – Cellular theory of immunity via phagocytosis by macrophages and microphages (polymorhonuclear leukocytes) (
Elie Metchnikoff)
1885 – Introduction of concept of a "therapeutic vaccination". Report of a live "attenuated" vaccine for rabies (
Louis Pasteur and
Pierre Paul Émile Roux).
1960 – Discovery of lymphocyte "blastogenic transformation" and proliferation in response to mitogenic lectins-phytohemagglutinin (PHA) (
Peter Nowell)
2010 – The first autologous cell-based cancer vaccine,
Provenge, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer.
2010 – First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of stage IV melanoma
2011 –
Carl H. June reports first successful use of CAR T-cells expressing the 4-1BB costimulatory signaling domain for the treatment of CD19+ malignancies
2014 – A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma.
Pembrolizumab and
nivolumab are approved within months of each other.
2016 – The role of dendritic cell expressed CTLA-4 in Th immune polarization is first described
2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (
atezolizumab), is approved for the treatment of bladder cancer
2017 – First autologous CAR T-cell therapy
tisagenlecleucel approved for the treatment of pediatric B-ALL; second autologous CAR T-cell therapy
axicabtagene ciloleucel (Yescarta) is approved.
2020 – The first
mRNA vaccines (
BNT162b2,
mRNA-1273), are developed for
SARS-CoV-2 infection; this new technology completed design, testing, and emergency approval in under one year.
^Hoption Cann SA, van Netten JP, van Netten C (1 January 2006). "Acute infections as a means of cancer prevention: opposing effects to chronic infections?". Cancer Detection and Prevention. 30 (1): 83–93.
doi:
10.1016/j.cdp.2005.11.001.
PMID16490323.
^Dupuytren G. "De la gangrène spontanée générale et partielle des tumeurs cancéreuses du sein". J Hebdom Med. 4.
^Wei MQ, Mengesha A, Good D, Anné J (January 2008). "Bacterial targeted tumour therapy-dawn of a new era". Cancer Letters. 259 (1): 16–27.
doi:
10.1016/j.canlet.2007.10.034.
PMID18063294.